|
|
|
|
| LEADER |
02999nam a22003015i 4500 |
| 001 |
000290286 |
| 005 |
20210907144319.0 |
| 007 |
cr nn 008mamaa |
| 008 |
170927s2017 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319588117
|
| 024 |
7 |
|
|a 10.1007/978-3-319-58811-7
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Phosphodiesterases: CNS Functions and Diseases /
|c edited by Han-Ting Zhang, Ying Xu, James M. O'Donnell.
|
| 250 |
|
|
|a 1st ed. 2017.
|
| 260 |
# |
# |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2017.
|
| 300 |
|
|
|a XIX, 471 p. 44 illus., 36 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in Neurobiology,
|v 17
|
| 505 |
0 |
|
|a Part I. PDEs and Signaling, Circuitry, and Implications of CNS Functions and Disorders -- 1. Phosphodiesterase Diversity and Signal Processing within cAMP Signaling Networks -- 2. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry -- 3. Interaction of Cdk5 and cAMP/PKA Signaling in the Mediation of Neuropsychiatric and Neurodegenerative Diseases -- 4. The PDE4 cAMP-specific Phosphodiesterases: Targets for Drugs with Antidepressant and Memory-enhancing Action -- 5. Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-related Metabolic Diseases -- Part II. PDEs in Cognition of Aging and Alzheimer’s Disease -- 6. From age-related Cognitive Decline to Alzheimer’s Disease: A Translational Overview of the Potential role for Phosphodiesterases -- 7. The Past, Present, and Future of Phosphodiesterase-4 Modulation for age-induced Memory Loss -- 8. A Role for Phosphodiesterase 11A (PDE11A) in the Formation of Social Memories and the Stabilization of Mood -- 9. Role of PDE9 in Cognition -- Part III. PDEs in Parkinson’s and Huntington’s Diseases -- 10. Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson’s Disease -- 11. Role of Phosphodiesterases in Huntington's Disease -- Part IV. PDEs and Psychiatric Disorders -- 12. The role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders -- 13. Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction -- 14. PDE Inhibitors for the Treatment of Schizophrenia -- Part V. PDEs and Others -- 15. Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence -- 16. Genetic Understanding of Stroke Treatment: Potential role for Phosphodiesterase Inhibitors -- 17. A unique sub-pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS.
|
| 650 |
|
0 |
|a Neurosciences.
|
| 650 |
1 |
4 |
|a Neurosciences.
|
| 700 |
1 |
|
|a Zhang, Han-Ting.
|e editor.
|
| 700 |
1 |
|
|a Xu, Ying.
|e editor.
|
| 700 |
1 |
|
|a O'Donnell, James M.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|